An evidence-based treatment for a Multiple Sclerosis (MS) relapse is an intravenous administration of 3-5 g of Methylprednisolone. In case of insufficient effect or corticosteroids intolerance, the therapeutic plasma exchange (TPE) is indicated. To assess the clinical effect of TPE in treatment of relapse in patients with relapsing-remitting MS (RRMS), we enrolled 155 patients meeting the following criteria (study period: January 2011 to February 2021): (1) age > 18, (2) RRMS according to the McDonald´s 2017 criteria, (3) MS relapse and insufficient effect of corticosteroids/corticosteroids intolerance, (4) baseline EDSS < 8. Exclusion criteria: (1) progressive form of disease, (2) history of previous TPE. Following parameters were monitored: EDSS changes (before and after corticosteroid treatment, before and after TPE; EDSS after TPE was assessed at the next clinical follow-up at the MS Center), and improvement of EDSS according to the number of procedures and baseline severity of relapse. 115 females (74%) and 40 males (26%) were included. The median age was 41 years (IQR 33-47)-131 patients underwent the pulse corticosteroids treatment and TPE, while 24 patients underwent only TPE without any previous corticosteroid treatment. Median baseline EDSS was 4.5 (IQR 3.5-5.5), median EDSS after finishing steroids was 4.5 (IQR 4.0-5.5). EDSS prior to the TPE was 4.5 (IQR 4-6), EDSS after TPE was 4.5 (IQR 3.5-5.5). We observed a significant improvement in the EDSS after TPE (p < 0.001). Sex differences were seen in TPE effectiveness, with median improvement of EDSS in females being -0.5 (IQR 1-0) and in males being 0 (IQR -0.5 to 0), p = 0.048. There was no difference in EDSS improvement by age category: 18-30 years, 31-40 years, 41-50 years, > 50 (p = 0.94), nor by total TPE count (p = 0.91). In this retrospective study of patients with an aggressive relapse and insufficient effect of intravenous corticosteroid treatment, a significant effect of TPE on EDSS improvement was observed. There was no significant difference in TPE effectivity according to the number of procedures, age, nor severity of a relapse. In this cohort, TPE was more effective in females.

Blood Centre University Hospital Ostrava Ostrava Czech Republic

Department of Clinical Neurosciences Calgary Stroke Program University of Calgary Calgary Canada

Department of Clinical Neurosciences Faculty of Medicine University Ostrava Ostrava Czech Republic

Department of Neurology University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Claflin SB, Broadley S, Taylor BV. The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta-analyses. Front. Neurol. 2019;10:1. doi: 10.3389/fneur.2018.01150. PubMed DOI PMC

Walton C, et al. (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Scleros. J. 2020;26:1816–1821. doi: 10.1177/1352458520970841. PubMed DOI PMC

Correia I, et al. Plasma exchange in severe acute relapses of multiple sclerosis—Results from a Portuguese cohort. Mult. Scler. Relat. Disord. 2018;19:148–152. doi: 10.1016/j.msard.2017.12.001. PubMed DOI

Kalincik T. Multiple sclerosis relapses: Epidemiology, outcomes and management A systematic review. Neuroepidemiology. 2015;44:199–214. doi: 10.1159/000382130. PubMed DOI

Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: Relationship to neurologic disability. Curr. Opin. Neurol. 1999 doi: 10.1097/00019052-199906000-00008. PubMed DOI

Lassmann H. Multiple sclerosis pathology. Cold Spring Harbor Perspect. Med. 2018;8:1. doi: 10.1101/cshperspect.a028936. PubMed DOI PMC

Hirst C, et al. Contribution of relapses to disability in multiple sclerosis. J. Neurol. 2008;255:1. doi: 10.1007/s00415-008-0743-8. PubMed DOI

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1. doi: 10.1212/01.WNL.0000096175.39831.21. PubMed DOI

Blechinger S, et al. Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses: A retrospective two-center study. Ther. Adv. Neurol. Disord. 2021;14:1. doi: 10.1177/1756286420975642. PubMed DOI PMC

Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif. 2009;28:108–115. doi: 10.1159/000224630. PubMed DOI

Reys, D. S.

Padmanabhan, A. PubMed

Cortese I, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294–300. doi: 10.1212/WNL.0b013e318207b1f6. PubMed DOI PMC

Navarro-Martínez R, Cauli O. Therapeutic plasmapheresis with albumin replacement in alzheimer’s disease and chronic progressive multiple sclerosis: A review. Pharmaceuticals. 2020;13:1. doi: 10.3390/ph13020028. PubMed DOI PMC

Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985;35:1. doi: 10.1212/WNL.35.3.312. PubMed DOI

Lipphardt M, Wallbach M, Koziolek MJ. Plasma exchange or immunoadsorption in demyelinating diseases: A meta-analysis. J. Clin. Med. 2020;9:1–19. doi: 10.3390/jcm9051597. PubMed DOI PMC

Stork L, et al. Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurol. 2018;75:1. doi: 10.1001/jamaneurol.2017.4842. PubMed DOI PMC

Dorst J, et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine. 2019;16:98–106. doi: 10.1016/j.eclinm.2019.10.017. PubMed DOI PMC

Brochet B, et al. Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis. J. Clin. Apher. 2020;35:281–289. doi: 10.1002/jca.21788. PubMed DOI

Havrdova, E. , Pitha J, Nytrova P & Liba Z. KKNEU0031 – Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího šíršího spektra, verze 2.0. Česká neurologická společnost ČLS JEP. https://www.czech-neuro.cz/content/uploads/2020/04/rs_odborna-2.0_final_pub_ web-2.pdf. (2020).

Weinshenker, B. G. PubMed

Magaña SM, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch. Neurol. 2011;68:870–878. doi: 10.1001/archneurol.2011.34. PubMed DOI PMC

Ehler J, et al. Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: A retrospective analysis of 90 patients. PLoS ONE. 2015;10:1. doi: 10.1371/journal.pone.0134583. PubMed DOI PMC

Lipphardt M, et al. Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J. Clin. Apher. 2019;34:381–391. doi: 10.1002/jca.21686. PubMed DOI

de Andrés, C. & Giménez-Roldán, S.

Habek M, Barun B, Puretić Z, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Therap. Apheres. Dialys. 2010;14:298–302. doi: 10.1111/j.1744-9987.2009.00794.x. PubMed DOI